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Abstract 
International public health workers are challenged by a burden of arthropod-borne disease that 
remains elevated despite best efforts in control programmes. With this challenge comes the 
opportunity to develop novel vector control paradigms to guide product development and 
programme implementation. The role of vector behaviour modification in disease control was 
first highlighted several decades ago but has received limited attention within the public health 
community. This paper presents current evidence highlighting the value of sub-lethal agents, 
specifically spatial repellents, and their use in global health, and identifies the primary challenges 
towards establishing a clearly defined and recommended role for spatial repellent products in 
disease control. 
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Background 
Arthropod-borne diseases, such as malaria and dengue, remain significant health problems 
worldwide despite decades of organized vector control [1,2]. The reasons for this are complex 
and include both limited option and availability of active ingredients (AIs), and a lack of 
understanding of all actions and mechanisms that such AIs exert against the target insects (Figure 
1). A better understanding of such actions would help in the design of alternative application 
formats for global vector control strategies beyond the current choices of insecticide-treated bed 
nets (ITNs) and indoor residual spraying (IRS). For decades, research and development in vector 
control have taken a secondary position to development of other methods of disease control – 
namely chemotherapy and vaccines. Simultaneously, the focus of efforts in vector control was on 
ITNs with minimal emphasis on other vector control strategies. As a consequence, there is now 
an urgent need to improve current tools and advance the development of novel products based on 
new paradigms that function through alternative mechanisms of action – i.e., vector behaviour 
modification that specifically includes spatial repellency. 
Figure 1 The general concept of spatial repellency is clear: to prevent an arthropod from 
entering a space occupied by a potential human host to reduce encounters between humans and 
vectors thereby eliminating or reducing the probability (risk) of pathogen transmission to either 
insect or human 
Currently, there are 15 AI compounds recommended by WHO for adult insect vector control 
restricted to only four chemical classes, with the most recent addition - etofenprox (pyrethroid) - 
occurring in 1999 [3,4]. Twenty years on, the global community continues to place expectations 
of population-level protection using these very same, limited groups of actives in the same way 
on walls of houses and bed nets. Although this limited arsenal of AIs and application modalities 
has contributed to decreasing the malaria burden, it is becoming grossly inadequate to sustain 
reductions in disease burden in many endemic countries. This is due, in part, to an overreliance 
on pyrethroids (which dominate the WHO shortlist of approved AIs) in both public health and 
agriculture and a resultant increasing occurrence of insecticide resistance, coupled with variable 
and poorly understood ecologies of different vector species [5]. 
No new classes of traditional vector control insecticides have been developed in recent decades 
(excluding reformulated active ingredients), therefore there is reason to assume that very few 
such compounds, if any, are currently in the development pipeline and expected for use in the 
near future. New AIs that have been explored and are ripe for development lack the important 
characteristic of repellency [6,7]. It is these significant behavioural effects, and alternative 
mechanisms of action that should be exploited for the development of innovative vector control 
products to better manage current and mitigate future insecticide resistance problems. The wider 
effort could be enhanced by broadening the scope of AI discovery to include screening criteria 
that identify compounds and/or chemical classes that exploit behavioural modification as a 
means to disease reduction [8]. 
The use of spatial repellents to create a vector-free space, thereby preventing contact between 
human and vector, thus preventing disease transmission, is demonstrably effective [9-22]. Yet, 
use of spatial repellency is neither endorsed nor recognized as a component of a multilateral 
disease control strategy. There are multiple rationales that argue in favour of a change in this 
policy. Benefits of sub-lethal over more conventional lethality-directed chemical approaches 
include: 1) marketable for insecticide-management purposes because its useful for delaying the 
onset of resistance to active ingredients used for ITNs or IRS; 2) effective for outdoor protection, 
something that IRS and ITNs have little impact on; 3) useful in attacking other components of 
vector behaviour such as pre, during and post-host-seeking, i.e. to disrupt critical behavioural 
sequences that can prevent blood-feeding (and disease transmission) and strengthen the 
effectiveness of integrated vector control strategies; 4) employable against multiple vectors, 
behaviours and species – not just those that feed and rest inside houses -and subsequently against 
other arthropod-borne diseases, and 5) useful against economically important insects, especially 
agricultural pests, where market forces will fuel the cost of AI discovery and development. 
Indeed, strategies such as a push-pull system that integrates repellents or mating disruptors with 
attractants and trapping methods, have successfully been implemented for agricultural pest 
control and are currently under investigation for vector control [23]. 
Incentives for changing the prevailing screening and evaluation paradigms for chemical control 
products should be driven through an evidence-based approach. Over the past several years, four 
formal national and international meetings [24] were convened to bring together academics, 
industry and global public health experts, including representatives from the WHO and the WHO 
Pesticide Evaluation Scheme (WHOPES) [25], to discuss the role of spatial repellent chemicals, 
whose effects are not reliant on acute toxicity or lethality, in the reduction of arthropod-borne 
diseases. A critical aspect of these meetings and subsequent efforts has been to establish a critical 
path of development for these products (SRCPD). The principal goal of the SRCPD is to gain 
formal acceptance of the requirement for the development and incorporation of spatial repellent-
based strategies as integral components for disease vector control from global health authorities 
such as WHOPES. As such, the adoption of a widely accepted SRCPD is expected to create 
opportunities and impetus for industry, academia and other private/public sector entities to 
increase ongoing efforts to discover, validate and develop novel repellent AIs that represent 
classes of chemicals that focus on vector behavioural modification rather than toxicity/lethality 
as well as find new means of utilizing existing compounds in behavioural disruption. This 
strategic document is expected to aid in a comprehensive effort to develop and eventually deploy 
innovative control methods for either stand-alone products and/or integrated interventions for 
combating vector-borne diseases. 
The intention of this paper is to disseminate key outcomes of the core working group, to 
highlight known and potential benefits of spatial repellency, identify specific obstacles and 
challenges to the successful development of spatial repellent tools, and to highlight key 
components of the “weight of evidence” needed to achieve the goal of recommending spatial 
repellents as a viable means for disease prevention (Table 1). 
Table 1 Summary points outlining role of spatial repellents and requirements for adoption 
in vector control 
Summary Points 
• The discovery, development and use of novel vector control tools will be required to 
achieve the goal of malaria elimination and eradication 
• Evidence exists of the benefits of sub-lethal approaches for interrupting human-vector 
contact but epidemiological data is insufficient to influence policy-makers to recommend 
spatial repellent tools for disease control confidently 
• The adoption of a new paradigm shift in vector control to include behavior modification will 
require a new set of laboratory and field assay tools, standardized endpoints and analyses 
which must also be endorsed and adopted by leading global public health authorities 
Making choices: repel or kill? Evidence of value 
Spatial, or area repellents (also known as deterrents [26]) are defined here as chemicals that work 
in the vapor phase to prevent human-vector contact by disrupting normal behavioural patterns 
within a designated area or “safe zone” (e.g. a space occupied by potential human hosts) thus 
making the space unsuitable for the insect (Figure 2). Depending on efficacy of the AI and 
application modality, this would result in a vector-free (or greatly reduced / suppressed) area. 
The unique benefit of SR is that the safe-zone can include specific areas both indoors and 
outside. The volume of space that is ‘protected’, or minimum protection range, will be dependent 
on the properties of the AI, application platform and/or environmental conditions (e.g. air flow, 
temperature and humidity). Regardless of the particulars, the general concept of spatial 
repellency is clear: to discourage an arthropod from entering a space occupied by a potential 
human host thus reducing encounters between humans and vectors thereby eliminating or 
reducing the probability (risk) of pathogen transmission to either insect or human. 
Figure 2 The fundamental choice between killing mosquitoes and deterring them: 
mosquitoes that abort attacks on humans because of sub-toxic exposure are, by definition, not 
exposed to toxic levels that kill them (Killeen GF and Moore SJ with permission) 
The current prevailing strategic paradigm in vector control is that effective delivery of an acutely 
toxic compound will have the greatest impact for disease suppression by reducing the survival of 
the overall vector population, a concept based on the classic Ross-Macdonald model used for 
advocating DDT IRS during the Global Malaria Elimination Programme in the 1950s-1960s. If 
correct, what is the rationale for removing or otherwise deterring a vector from a specified space 
without directly killing it? If spatial repellency to prevent bites were to be the primary control 
mechanism, malaria transmission will be reduced if mosquitoes 1) are diverted to alternative 
non-human hosts which cannot carry malaria, and/or 2) feed, reproduce and survive less because 
humans are difficult to access and no alternative source of blood is available [19]. The result will 
be reductions in numbers of both humans and vectors being infected and this result has a 
dramatic effect on mathematical models of malaria transmission [27]. 
The immediate advantages of modifying vector behaviour that results in movement away from a 
human host, is a delayed or diminished development in the emergence of insecticide resistance 
by minimizing the intensity of selection pressure from contact-mediated toxicity mechanisms as 
well as the potential reduction of toxic effects of a chemical to human and non-target organisms. 
The added long-term benefits of demonstrating disease impact of spatial repellents include the 
discovery and development of new chemical active ingredients and/or new modes of action that 
target and exploit the normal vector behavioural patterns outside and surrounding the home 
while in search of a host. A better understanding of vector behaviour in this context can stimulate 
innovative product development and enhance vector control. The accumulated long-term effects 
of such deterrent events upon mosquito life histories can reduce malaria transmission by forcing 
mosquitoes to either feed upon non-human hosts or to search more broadly for alternative blood 
(and subsequently oviposition sites), thereby reducing human blood indices, vector survival, 
feeding frequency and reproduction rates. It is likely that, the longer a vector remains exposed to 
harsher and more demanding outdoor conditions the more likely it is that the vector will die. 
Outdoors, vectors risk greater predation, physiological stressful environments, and excessive 
energy expenditure during host-seeking, or identifying a resting or oviposition site [19]. In 
essence, the vector population will potentially experience greater adverse environmental 
exposure and therefore mortality without chemically induced selection pressure thereby 
potentially increasing the sustainability of existing and novel chemical interventions. 
Furthermore, vector populations that survive exposure to sub-lethal, spatial repellents may 
subsequently show permanent or semi-permanent disruption of host-seeking and blood-feeding 
behaviours [28]. The reduction in host-contact/feeding success could ultimately lead to reduced 
overall numbers and survival of older mosquitoes that transmit mature infectious stage parasites, 
thereby suppressing transmission at the community level –a more subtle means to achieve the 
desired outcome of traditional adulticidal strategies [19]. 
The case for developing a SRCPD is strengthened by several research programmes that have, 
and continue, to generate evidence of the benefits of sub-lethal approaches for disease control. 
Studies evaluating physical barriers (e.g. house screening and untreated bed nets) have shown 
reduction on disease burden in the absence of vector lethality [20,21]. Specifically, a randomized 
controlled trial where screening houses resulted in a 50 % reduction in malaria vectors entering 
the house, produced a 50 % reduction in anaemia in young children. In this study, houses were 
screened with untreated netting and, since they ‘repelled’ mosquitoes and did not kill them, they 
were protected in a similar manner to that expected for spatial repellents. Further evidence exists 
describing the potential effects of sub-lethal toxic chemicals and disease reduction [9-22]. 
Indeed, beginning in the 1940s, numerous observations were made on the ability of DDT 
(arguably the most effective chemical tool so far developed to reduce arthropod-borne disease 
burden in history) to create a vector-free space [29]. When DDT was sprayed on the interior wall 
surfaces of houses, there were essentially no mosquitoes to be found indoors, with malaria rates 
subsequently declining dramatically and vector populations were reduced overall [10,11,17]. 
Those results are attributed primarily to the spatial repellent action of DDT (a significant and 
generally underrated property) and not the toxic action alone [30]. This conclusion is based on 
numerous observational and quantitative studies that clearly indicate the primary action of DDT 
is spatial repellency with ‘irritancy’ (contact excitation) and toxicity as secondary and tertiary 
effects of lower order [12-19]. Furthermore, a dramatic and unmistakable reduction in disease 
incidence has been documented following IRS with DDT even in areas with significant DDT-
resistant vector populations [31]. This paper is not designed to argue the use of DDT in vector 
control programs. Instead, it aims to highlight the spatial repellent characteristics of the AI to 
provide a significant example of the role and value of behavior modification in disease control. 
A paradigm shift from contact toxicity-based strategies to a broader approach using behaviour-
modifying AIs and modalities that can operate safely at a distance, will require clear evidence 
that demonstrate: 1) chemicals can exert behaviour-modifying characteristics relating to 
vector/host interactions (via entomological validation); 2) that peripheral exposure to such 
chemicals is not harmful or otherwise unfavourable to humans, and 3) sub-lethal approaches to 
vector control can significantly impact disease transmission (via epidemiological validation). Of 
these, chemical-based behaviour modification has been comprehensively demonstrated under 
both laboratory and field conditions [12-16]. Although historical data exists supporting the 
associated sub-lethal effects on disease risk reduction [10,17], no controlled study design has 
been implemented to specifically correlate spatial repellency actions with direct, real-time impact 
on disease incidence. 
Expectations 
Human populations have long been aware that using personal repellents and deterrents can 
reduce biting from blood-sucking insects and utilize these materials widely, even when 
associated with marked financial costs [32]. In economies that can support even minimal 
discretionary spending, it is not uncommon to observe use of electric fans or topical repellents to 
reduce biting burden and/or the purchase of various commercial products, including insecticidal 
powders, aerosols, nets, and coils that function by toxic (acute-kill) chemical actions. Spatial 
repellent actives could be integrated into such consumer products or used to enhance IRS and 
ITN programmes, where appropriate, to provide added protection to individuals, households and 
communities using active ingredients with minimal mammalian toxicity. However, the public 
health community must think beyond current formats and consider novel consumer-based 
products that increase market value and thereby compliance and sustainability by combining 
end-user “wants” (i.e. products that provide utility or beautification, such as decorative mats, 
clothing, etc.) with vector control thereby creating opportunities for innovative cost-effective and 
affordable vector control delivery platforms. Marketing these tools through a consumer product 
channel poses a viable solution to managing burden of product delivery to target populations 
[32]. 
It is realistic to conceptualize a spatial repellent product that can be adapted to exterior areas of 
homes or within the immediate peri-domestic environment to effectively protect a wider spatial 
area from pathogen transmission throughout both evening and daytime hours. In fact, in the face 
of elimination/eradication of malaria, it is becoming more evident that those vectors with 
behaviours which are not controlled by conventional IRS and ITNs or spaces where physical 
structures are absent, will become the focus of residual transmission and will be the barrier to 
success or failure [26,33]. When one considers the human population at risk of transmission 
outdoors, the niche for spatial repellents becomes increasingly evident due to the lack of current 
control products for those humans becoming infected in these areas [34,35] (Figure 3). What 
tools we currently have are not enough. The role of combined organized vector control (IRS and 
ITNs) with personal protection (consumer products) to enhance human protection from infection 
is upon us and where SR could equally be useful. 
Figure 3 An outdoor role for spatial repellents? Mathematical models show that the best 
strategy for application of spatial repellents depends on the vector. Indoors and outdoors use is 
best for those vectors least susceptible to LLINs/IRS, while use of spatial repellents outdoors is 
best to complement LLINs/IRS in areas where vectors feed indoors on humans (Killeen, GF and 
Moore, SJ with permission) 
Such products could be disseminated in a variety of delivery platforms: as stand-alone consumer 
products or designed to be integrated into community-based or vertically organized vector 
control programmes. By applying separate products with very different, complementary modes 
of action to distinct fractions of transmission sites, it may be possible to both extend rather than 
duplicate coverage of transmission per se and exploit the benefits of SR against direct-toxicity. 
Given that repellent actions and mechanisms are independent of toxicity and the necessity for 
direct contact with a treated surface is averted, the authors envision a spatial repellent active 
ingredient that is effective against various genera and species of disease vectors, either 
insecticide resistant or susceptible, that can be adapted to a plethora of conditions. 
Hurdles to overcome 
In order for a spatial repellent product to enter into the market, a set of development criteria must 
be met. These include measures related to scientific, regulatory and social parameters. In part, 
these criteria will comprise the SRCPD and outline the endpoints of a target product profile for a 
spatial repellent product. The authors have chosen to describe three major hurdles identified in 
the SRCPD (Table 2). 
Table 2 Key areas for strategic investment in spatial repellent research 
Key Areas for Strategic Investment in Spatial Repellent Research 
1 Proof-of-Concept: demonstrating a spatial repellent will impact disease at the community 
level 
2 Correlating entomological endpoints with reduction in infection incidence rates using 
repellent tools 
3 Measuring the impact of diversion of repelled vectors to untreated sources under varying 
transmission dynamics 
4 Defining the limitations of spatial repellency in both susceptible and insecticide resistant 
vector populations 
5 Developing standardized protocols and measures for the evaluation of vector behavior 
modification as it relates to host-feeding following exposure to spatial repellents (i.e., host-
seeking, feeding, resting, and oviposition) to identify long-term effects of spatial repellents 
6 Engagement and recruitment of industry and academic partners to adopt standardized 
protocols and measures for the screening of chemical AIs to include spatial repellency 
7 Identifying the underlying genetic/neurobiological basis of vector behaviors to provide 
insight into the rationale design of new repellents 
1. Generation of sufficient epidemiological data to influence policy-makers to recommend 
the incorporation of spatial repellents into current multi-lateral disease control 
programmes confidently. The concept of spatial repellency will be accepted provided that 
indisputable proof of principle that a spatial repellent can reduce human disease through sub-
lethal chemical actions. While associations between spatial repellency and reduced disease 
transmission have been made, they generally exist in two incomplete formats: epidemiological 
data post-chemical treatment that lacks a sufficient entomological component or evaluation of 
changes in entomological endpoints due to repellency without supporting case data that measures 
disease impact [9-22]. To date, no published accounts linking epidemiological and entomological 
components exist for spatial repellents, thus there is a critical need for Phase III community trials 
integrating simultaneous monitoring of infection incidence with vector population metrics (i.e. 
parity, sporozoite rates, blood meal indices, abundance etc.), one of which is currently underway. 
Such confirmatory studies will require unambiguous entomological measures of repellency 
versus irritancy and/or knock down effects in reducing vector entry into a given interior space or 
outside area, as well as reductions in vector biting densities (to include potential redirection to 
untreated spaces with human hosts) concurrent with reduced pathogen transmission. The 
challenge arises when designing an impact study to ensure both entomological and 
parasitological endpoints correlate with true repellency effects. 
2. Identification and validation of the entomological end points that predict a public health 
impact using spatial repellency. There are three active ingredients currently registered by the 
USEPA for outdoor use as vaporizing spatial repellents (allethrin, pyrethrins and metofluthrin). 
Prallethrin, permethrin and cyflutrhin when used as aerosols and/or surface sprays also have 
spatial repellency claims. However, the endpoint used to label them as spatial repellents is anti-
biting. These pyrethrum and pyrethroid-based products are all known to have knock down and 
toxicity at defined concentrations. These products may be sufficient to achieve our public health 
goals. If they are not, then effective screening systems will have to be established. A critical 
element of that process will be establishing end points. Currently, there is no consensus about 
what those end points may be and the best means to quantify them. Critical endpoints may 
include reduced entry into a treated space, reduced abundance within a space, and enhanced exit 
from a space. Furthermore, the end points will have to be accurately quantified. How far must 
any of those measures have to shift in order to create a reduction in pathogen transmission? How 
do shorter 24-hour measures of those parameters, currently used in routine testing, relate to the 
cumulative impact over the days or weeks of a transmission season? Once the end points for 
evaluating spatial repellency have been established (identified and validated) effective screening 
can begin. We will need to lobby our industry partners to engage in the systematic screening of 
spatial repellency in either existing chemical libraries and/or discovery of novel chemical classes 
for vector control. 
3. Motivating an objective, universally acceptable paradigmatic shift in the current 
screening protocols for the assessment and discovery of chemical vector control products. 
In order to generate spatial repellent products, the scientific community must have well defined, 
effective active ingredients. Current laboratory screening protocols utilize knock down and 
mortality as sole criteria for advancing compounds to the next level in the screening process [8]. 
Even with disease impact studies and a vast market potential for repellent products there will be 
a requirement to adopt, via scientific community consensus, a new set of laboratory and field 
assay tools, standardized endpoints and analyses. These must come from a consensus within the 
scientific and development communities and must be sufficiently clear and uniform to provide 
reliable and reproducible results to evaluate behavioural responses of a candidate spatial 
repellent. In order to promote worldwide recognition of spatial repellents for use in vector 
control, these new testing protocols and overall evaluation schemes must also be endorsed and 
adopted by leading public health authorities such as WHOPES. Currently, WHOPES has 
standard evaluation protocols for insecticides as contact irritants, bed nets, and aerosols; 
however, there is an absence of standard protocols for evaluating the behavioural effects of 
spatial repellent AIs with corresponding endpoints. It is expected that a screening cascade will 
need to be developed to allow the step-wise identification of candidate compounds. This cascade 
should exploit each assay’s sensitivity in an ordered, procedural manner. For example, the 
process could begin with high-throughput to include an intracellular evaluation (i.e., gene 
expression and/or electrophysiological responses) or novel molecular target that can be screened 
via heterologous expression platforms. Discovery-based efforts would then advance to a 
laboratory and then semi-field behavioural systems, through to controlled experimental hut 
studies under field conditions. One essential part of this process will be to define the mode(s) of 
action of active ingredients that elicit the desired behavioural effect. This fundamental 
information will aid the development of effective and efficient screening tools and means of 
exploiting new AIs. The promising news is that there are several electrophysiological and 
behavioural assays with correspondingly robust analyses currently being used in vector biology 
research that could be incorporated into such schemes once adopted by WHOPES and the wider 
scientific community [16,36-42]. 
Future directions 
The ultimate goal of this working group is to provide a basis for the recommendation by public 
health authorities for the incorporation of spatial repellent products in multi-lateral efforts 
focused on disease vector control. The success of this effort will depend on a concerted effort 
between public health entities, regulators, industries, non-governmental agencies and sponsors, 
and academic partnerships coordinated through a formal consortium which the authors now 
propose: Advancing Repellency to Recommendation (ARRC) to facilitate the planning, 
implementation and data dissemination for priority research studies as outlined in the SRCPD. 
The focus of ARRC will be to continue developing a structured effort to increase the number of 
potential and efficacious spatial repellent tools following a precise SRCPD format beginning 
with the identification of priority research areas. Combined, datasets from these studies will 
provide insight into the rational design of new repellent active ingredients, establish critical 
baseline data and generate consensus on essential outcome measures and data interpretation 
required for evaluation of the efficacy of repellent products and control strategies. 
Summary 
Despite many decades of concerted effort along a number of fronts, the long and difficult battle 
to control vector-borne diseases continues. It is incumbent on the international disease control 
community to step up to this challenge and embrace both the need and opportunity for 
innovation. It is accepted this includes not only the attempt to use available tools optimally but 
also develop new ones to improve vector control. The authors take the view that control of 
pathogen transmission by preventing vectors from entering human-occupied spaces is both 
beneficial and cost-effective and that efforts to dramatically increase investments and efforts to 
develop novel spatial repellent tools and strategies are urgently needed. 
Paradoxically, the value of vector behaviour modification in disease control has been recognized 
for many decades but largely under-appreciated. As a consequence, it is likely that potentially 
effective chemicals and novel products have been missed or overlooked. With current efforts 
focused on the elimination and eventual eradication of vector-borne diseases such as malaria, this 
must change [43]. It is the authors’ goal that this article will bring renewed awareness, 
stimulation and focus to the importance of spatial repellency as an effective tool in the fight 
against vector-borne disease transmission. By doing so it is hoped that further discussion and a 
sustained investment in R&D will be quickly forthcoming in order to bring a new generation of 
effective chemicals and novel products into the disease control/eradication armamentarium. 
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F i g u r e 5 .
Key Areas for Strategic Investment in Spatial 
Repellent Research 
 
1) Proof-of-Concept: demonstrating a spatial repellent will 
impact disease at the community level  
 
2) Correlating entomological endpoints with reduction in 
infection incidence rates using repellent tools  
 
3) Measuring the impact of diversion of repelled vectors to 
untreated sources under varying transmission dynamics  
 
4) Defining the limitations of spatial repellency in both 
susceptible and insecticide resistant vector populations 
 
5) Developing standardized protocols and measures for the 
evaluation of vector behavior modification as it relates to 
host-feeding following exposure to spatial repellents (i.e., 
host-seeking, feeding, resting, and oviposition) to identify 
long-term effects of spatial repellents  
 
6) Engagement and recruitment of industry and academic 
partners to adopt standardized protocols and measures for 
the screening of chemical AIs to include spatial repellency  
 
7) Identifying the underlying genetic/neurobiological basis of 
vector behaviors to provide insight into the rationale design 
of new repellents  
Figure 4
F i g u r e 2 .
Summary Points 
 
‚ The discovery, development and use of novel vector control 
tools will be required to achieve the goal of malaria 
elimination and eradication 
 
‚ Evidence exists of the benefits of sub-lethal approaches for 
interrupting human-vector contact but epidemiological data is 
insufficient to influence policy-makers to recommend spatial 
repellent tools for disease control confidently 
 
‚ The adoption of a new paradigm shift in vector control to 
include behavior modification will require a new set of 
laboratory and field assay tools, standardized endpoints and 
analyses which must also be endorsed and adopted by 
leading global public health authorities  
Figure 5
